TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05861414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EWM-T
Description: This paradigm was adapted from the n-back program described by Jaeggi et al. (2009) and comprised an affective dual n-back task consisting of a series of trials, each of which simultaneously presented a face (for 500 ms) on a 4 × 4 grid on a monitor. Intermediate interval 2500ms, during which, Participants press a button to determine if the current face or position is consistent with the first n. If the position is the same, press F; if the face is the same, press J; if the face and position are not the same, do not react.~The faces used in this training were selected from the Chinese Facial Emotional Picture System (CFAPS), and 12 faces (six male and six female) with fear, anger, disgust, and sadness were selected as n-back experimental materials.
Study: NCT04912843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NR082 injection
Description: Intravitreal injection（IVT）

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: Sham Intravitreal Injection
Study: NCT05970250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration group
Description: Whole body vibration apparatus (model Power plate -my5tm, made in United States) with frequency 30 - 40 Hz was used for the whole body vibration program by reciprocating vertical displacements on the left and right side of a fulcrum.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight bearing exercises
Description: Electronic treadmill Kettler- marathon model No 7899-800, made in Germany (as form of weight bearing exercises), which was adjusted to the subject's comfortable walking speed. Generally, during the treadmill training, its speed and inclination are electronically adjusted, and it is also provided with a control panel to display the exercise parameters. It allows for the comfortable running without joint or back pains through a perfect combination between aluminium-pertinax running deck, shock absorbers and overall shock-damping design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D supplements and calcium
Description: vitamin D supplements and calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D supplements and calcium
Description: vitamin D supplements and calcium

Intervention type: DRUG
Group type: OTHER
Intervention: vitamin D supplements and calcium
Description: vitamin D supplements and calcium
Study: NCT05179070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: the first is the rapid up-titration group, which will get carvedilol up-titration every day, 3.125mg twice daily on the first day, 6.125mg twice daily on the second day, 12.5mg twice daily on the third day and 25mg twice daily on the fourth day consecutively. And the second group will have carvedilol titration according to established guidelines on Heart Failure, start 3.125mg twice daily, and up titrated every 2 weeks
Study: NCT06261632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: The intervention protocol through blood flow restriction in patients with hemophilic arthropathy will include performing squats and knee extension for 5-10 and 10 minutes respectively. In both exercises, 4 series will be performed (30, 15, 15, 15 repetitions) with 30 seconds of rest between series
Study: NCT05925231

Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: 3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test

Intervention type: DIAGNOSTIC_TEST
Intervention: Box and Block Test
Description: 3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test
Study: NCT05510427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by (IV) vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by (IV) vein
Study: NCT05074953

Intervention type: OTHER
Intervention: Exposed to a SARS-CoV-2 infection
Description: The study compared humans exposed to the SARS-CoV-2 infection with a matched group of those not exposed. No Intervention was applied.
Study: NCT05292859

Intervention type: BIOLOGICAL
Intervention: Neoantigen specific TCR-T cell drug product
Description: No study drug is administered in this study. Patients who have received Neoantigen specific TCR-T cell drug product will be evaluated in this trial for long-term safety and efficacy
Study: NCT04796766

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High frequency stimulation (HFS)
Description: Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High frequency stimulation (HFS)
Description: Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High frequency stimulation (HFS)
Description: Electrical stimuli via circular electrode array. The electrode array serves as cathode placed above the eyebrow. A surface electrode (anode) will be placed on the temple. Electrical stimuli will be applied via a constant current stimulator. The stimulus intensity for the electrophysiological protocol is adjusted to the 10-fold of the detection threshold. A number of 5 electrical pulses (2 ms, 100 Hertz (Hz)), 10 second intervals.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-frequency sinusoidal transcutaneous stimulation (sLFS)
Description: Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-frequency sinusoidal transcutaneous stimulation (sLFS)
Description: Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Low-frequency sinusoidal transcutaneous stimulation (sLFS)
Description: Stimulation of C-nociceptors with constant current stimulator. Electrodes (placed on the proband's forehead. Stimulation by sine wave pulses of 250 ms duration (4 Hz), intensities inducing a pain intensity of 50/100 on a visual analogue scale from 0-100.
Study: NCT05780138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Taking Action
Description: Educational intervention designed to provide caregivers of children with autism information about autism, and strategies to advocate and support their child's development.
Study: NCT06487130

Intervention type: OTHER
Intervention: N/A Observational Registry
Description: Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.

Intervention type: OTHER
Intervention: N/A Observational Registry
Description: Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.

Intervention type: OTHER
Intervention: N/A Observational Registry
Description: Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.

Intervention type: OTHER
Intervention: N/A Observational Registry
Description: Registry participants may select to be contacted for future research and/or embedded clinical trials. Such interventions will require associated ethics review \& approval.
Study: NCT04797052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefrontal EEG (VEEGix by NeuroServo)
Description: Prefrontal EEG reading
Study: NCT04199624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: Omeprazole twice daily x 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Ascorbic acid x 1 on day 5
Study: NCT05410639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: online education program
Description: The training we provided was to give exercises and advice to parents according to the age of the baby in order to stimulate the motor and social development of the baby,and then, an improvement in the stress state of the parents by their participation in the care of their baby.The training, which began with the discharge of the baby from the hospital, was in the form of slide presentations and videos.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no online education program
Description: Parents and their infants in the control group did not receive any online education program
Study: NCT05601427

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: aACB
Description: The patient will undergo a pre-operative single-shot, ultrasound-guided ACB performed by an anaesthesiologist skilled in regional anaesthesia techniques. The ACB will be performed in a dedicated block room, immediately prior to administration of a spinal anaesthetic.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sACB
Description: The patient will undergo an intraoperative single-shot ACB performed by the treating surgeon following placement of the TKA components.
Study: NCT04735848

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-supplement application
Description: The participants will take the corresponding amount of iron-supplement supervised at 8am.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-supplement application
Description: The participants will take the corresponding amount of iron-supplement supervised at 8am.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-supplement application
Description: The participants will take the corresponding amount of iron-supplement supervised at 8am.
Study: NCT04555785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wilate
Description: Wilate ® will be given with platelets in cases of severe bleeding. Wilate ® is a 1:1 balanced mixture of von Willebrand Factor (2'000 IU) and Coagulation factor VIII (2'000 IU) and as such has anti-haemorrhagic potential. It is extracted from plasma, freeze-dried and virus-inactivated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Empty placebo will be given with platelets in cases of severe bleeding.
Study: NCT05483868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: Administration of AU-011 intratumorally and intramurally

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Adminstration
Description: AU-011 Intratumorally and Intramurally

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Administration
Description: AU-011 Intratumorally

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Administration
Description: AU-011 Intratumorally

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Administration
Description: AU-011 Intratumorally

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AU-011 in Combination with Medical Laser Administration
Description: AU-011 Intratumorally
Study: NCT06240117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative cellular salvage
Description: When the patient is randomized to this intervention the cell salvage machine will be set up for intraoperative use. The surgical team will collect blood from the surgical field into the cell salvage machine, which will process the blood for reinfusion. The volume of blood available for reinfusion is determined by the amount of blood lost which can be collected into the cell salvage system. The blood collected into the salvage system will be collected and processed per standard operating room procedure. At least 100mL of blood collected in the system are necessary for processing. If \>100mLs are collected, they will be processed and reinfused. The need for additional blood products and medications will be determined by the anesthesiology team based on the patient's hemodynamic status and will proceed per standard of care.
Study: NCT06406335

Intervention type: OTHER
Group type: OTHER
Intervention: Health education program
Description: Impact of A Multidimensional Health Education Program on Attention deficit hyperactivity disorder (ADHD)
Study: NCT05032144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSA-1002 injection
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study: NCT06018155

Intervention type: OTHER
Intervention: Spine surgery
Description: Cohort of patients suffering from low back pain and candidate to a spine surgery included in a database previously constituted
Study: NCT06323785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active whole-body hyperthermia
Description: Active water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
Study: NCT04891705

Intervention type: DEVICE
Intervention: Lung Ultrasound Scan
Description: Ultrasound scan of subjects in up to 14 lung zones

Intervention type: DEVICE
Intervention: Lung Ultrasound Scan
Description: Ultrasound scan of subjects in up to 14 lung zones
Study: NCT05686798

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS)
Description: Ad5-yCD/mutTKSR39rep-ADP adenovirus will be injected intratumoral
Study: NCT06323785

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham whole-body hyperthermia
Description: Sham water-filtered infrared whole-body hyperthermia as described in Janssen et al. (2016)
Study: NCT05251272

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: All patients underwent measurement of HVPG under local anesthesia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hepatic venous pressure gradient
Description: All patients underwent measurement of HVPG under local anesthesia.
Study: NCT01981668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
Study: NCT06287203

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addiction Risk Feedback Program
Description: This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addiction Risk Feedback Program
Description: This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Addiction Risk Feedback Program
Description: This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Addiction Risk Feedback Program
Description: This novel prevention/intervention program will be accessed via an on-line interactive website where individuals receive their personalized risk estimates, based on their genetic, behavioral, and environmental risk factors (part 1 of the program), accompanied by information to help them reduce risk (part 2 of the program). The information in part 2 of the program will vary between arms.
Study: NCT05844670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: The initial vincristine dosage will be according to institutional treatment protocol. After vincristine administration, three blood samples will be taken at T=1, T=1.5 and T=4 hours. The concentration of vincristine will be analyzed in the samples. If the concentration of 2 or more samples is lower than the reference concentration and there is no toxicity, an advice will be given to increase dosage by 20%. Whether or not a dosage is given, vincristine concentrations will be measured again for the next dose administration.~For the feasibility study, both venous blood samples and finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 2 times.~For the rest of the study, finger prick blood samples using Mitra tips will be taken. The cycle can be repeated maximum 3 times.~Toxicity will be monitored through physical exam and questionnaire, bilirubin levels and clinical status of the patient.
Study: NCT05926453

Intervention type: OTHER
Intervention: Maximal cardiorespiratory exercise test
Description: previously described
Study: NCT05872191

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention to be administered, only collection of data through various tests and questionnaires.
Study: NCT05484414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRP-3D (diethylamide)
Description: SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL
Study: NCT06464653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forel's Field H-DBS ON
Description: The surgical intervention named deep brain stimulation is a well-established neurosurgical treatment for drug-resistant epilepsy. The targets used in this study is Forel's Field H. The devices used for intervention have been approved by Chinese National Medical Products Administration (CFDA). The postoperative drug dosage adjustment depends on the efficacy of DBS and the judgment of the epilepsy specialist.
Study: NCT05788874

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI and 18F-FDG PET/CT
Description: 18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-FAPI and 18F-FDG PET/CT
Description: 18F-FAPI and 18F-FDG PET/CT for gastrointestinal cancer
Study: NCT05944575

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active taVNS
Description: The clip electrode will be attached to the cymba conchae of the left ear, the location of the auricular branch of the vagus nerve.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-taVNS
Description: The clip electrode will be attached to the lobule of the left ear that is not innervated by the auricular branch of the vagus nerve.
Study: NCT04522648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prospective surveillance
Description: A participant with an increase from pre-surgery in total arm volume of ≥6% by self-measurement, or symptoms of BCRL ≥2 NRS will receive an assessment by a lymphedema therapist. At this appointment, participants will receive a physical examination of the arm along with a BIS measurement. A participant is considered having subclinical BCRL if an increase in lymphedema index (L-DEX) ≥7 from pre-surgery measured by BIS is identified. A fitted compression garment and gauntlet is then provided, free of charge, for daily wear 10 hours/day for four weeks along with a recommendation to use the arm for daily activities and maintain regular physical activity. Following the four-week compression period, participants will be re-measured using BIS to evaluate response. Participants who do not respond to compression will receive CDT delivered by the lymphedema therapist.
Study: NCT05637034

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-F2 PET/CT and 18F-FDG
Description: Each subject receive a single intravenous injection of 68Ga-DOTA-F2 and 18F-FDG, and undergo PET/CT imaging within the specified time.